David Kessel Selected Research

ethyl 2- amino- 6- bromo- 4- (1- cyano- 2- ethoxy- 2- oxoethyl)- 4H- chromene- 3- carboxylate

5/2007	Initiation of apoptosis and autophagy by the Bcl-2 antagonist HA14-1.
4/2005	Susceptibility of myelomonocytic leukemia U937 cells to the induction of apoptosis by the non-peptidic Bcl-2 ligand HA14-1 is cell cycle phase-dependent.
9/2002	Apoptotic response to photodynamic therapy versus the Bcl-2 antagonist HA14-1.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David Kessel Research Topics

Disease

17	Neoplasms (Cancer) 09/2022 - 10/2003
6	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 04/2004
5	Leukemia L1210 12/2007 - 09/2002
3	Necrosis 01/2022 - 05/2011
2	Squamous Cell Carcinoma of Head and Neck 03/2021 - 01/2020
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 01/2020
2	Leukemia 05/2007 - 04/2005
1	Photosensitivity Disorders (Photodermatitis) 01/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021
1	Papillomavirus Infections 01/2020
1	Residual Neoplasm 01/2019
1	Phototoxic Dermatitis (Phototoxicity) 01/2019
1	Malignant Mesothelioma 01/2019
1	Mesothelioma 01/2019
1	Neoplasm Metastasis (Metastasis) 01/2019
1	Ovarian Neoplasms (Ovarian Cancer) 01/2019
1	Hypoxia (Hypoxemia) 01/2016
1	Esophageal Neoplasms (Esophageal Cancer) 11/2015
1	Inflammatory Breast Neoplasms 11/2015
1	Margins of Excision 07/2015
1	Vascular System Injuries 02/2014
1	Pathologic Constriction (Stenosis) 02/2010
1	Leukemia P388 11/2009
1	Ventricular Heart Septal Defects (Ventricular Septal Defect) 10/2009
1	Aneurysm (Aneurysms) 06/2007
1	False Aneurysm (Pseudoaneurysm) 06/2007
1	Fibrosarcoma 10/2003

Drug/Important Bio-Agent (IBA)

24	1-phenyl-3,3-dimethyltriazene (PDT)IBA 09/2022 - 09/2002
10	Photosensitizing Agents (Photosensitizers)IBA 01/2021 - 10/2003
6	Talaporfin (talaporfin sodium)IBA 11/2015 - 04/2004
3	ethyl 2- amino- 6- bromo- 4- (1- cyano- 2- ethoxy- 2- oxoethyl)- 4H- chromene- 3- carboxylateIBA 05/2007 - 09/2002
2	Pharmaceutical PreparationsIBA 01/2018 - 08/2015
2	Oxygen (Dioxygen)IBA 08/2015 - 07/2011
2	LigandsIBA 04/2005 - 09/2002
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021
1	temoporfinIBA 01/2021
1	CaspasesIBA 01/2021
1	Verteporfin (Visudyne)FDA Link 01/2019
1	LipidsIBA 01/2019
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019
1	Phosphotransferases (Kinase)IBA 01/2019
1	Therapeutic UsesIBA 01/2016
1	chlorinIBA 07/2014
1	Singlet OxygenIBA 01/2011
1	Carbon DioxideIBA 10/2009
1	porphyceneIBA 12/2007
1	monodansylcadaverineIBA 05/2007
1	Proteins (Proteins, Gene)FDA Link 05/2007
1	XK 469 (XK469)IBA 01/2007
1	Antineoplastic Agents (Antineoplastics)IBA 01/2007
1	N- (2- cyclohexyloxy- 4- nitrophenyl)methanesulfonamideIBA 03/2005
1	ChlorineIBA 03/2005
1	PorphyrinsIBA 02/2005
1	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 04/2004
1	Troleandomycin (TAO)FDA Link 04/2004
1	Peptide Hydrolases (Proteases)FDA Link 04/2004
1	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 10/2003
1	tin etiopurpurin (SnET2)IBA 10/2003

Therapy/Procedure

17	Photochemotherapy (Photodynamic Therapy) 09/2022 - 09/2002
4	Therapeutics 01/2019 - 02/2014
1	Chemoradiotherapy 03/2021
1	Radiotherapy 03/2021
1	Drug Therapy (Chemotherapy) 01/2019
1	Kidney Transplantation 02/2010
1	Cholecystectomy 06/2007
1	Ligation 06/2007